BLUEPRINT MEDICINES CORP (BPMC) Stock Price & Overview
NASDAQ:BPMC • US09627Y1091
Current stock price
The current stock price of BPMC is 129.46 USD. Today BPMC is up by 0.14%. In the past month the price increased by 0.96%. In the past year, price increased by 12.6%.
BPMC Key Statistics
- Market Cap
- 8.372B
- P/E
- N/A
- Fwd P/E
- 131.18
- EPS (TTM)
- -3.22
- Dividend Yield
- N/A
BPMC Stock Performance
BPMC Stock Chart
BPMC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BPMC. When comparing the yearly performance of all stocks, BPMC is one of the better performing stocks in the market, outperforming 87.01% of all stocks.
BPMC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BPMC. Both the profitability and financial health of BPMC have multiple concerns.
BPMC Earnings
On May 1, 2025 BPMC reported an EPS of -0.74 and a revenue of 149.41M. The company missed EPS expectations (-38.05% surprise) and missed revenue expectations (-5.77% surprise).
BPMC Forecast & Estimates
25 analysts have analysed BPMC and the average price target is 132.96 USD. This implies a price increase of 2.71% is expected in the next year compared to the current price of 129.46.
For the next year, analysts expect an EPS growth of 76.13% and a revenue growth 41.72% for BPMC
BPMC Groups
Sector & Classification
BPMC Financial Highlights
Over the last trailing twelve months BPMC reported a non-GAAP Earnings per Share(EPS) of -3.22. The EPS increased by 57.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.03% | ||
| ROE | -45.52% | ||
| Debt/Equity | 1.01 |
BPMC Ownership
BPMC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BPMC
Company Profile
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Company Info
IPO: 2015-04-30
BLUEPRINT MEDICINES CORP
45 Sidney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Jeffrey W. Albers
Employees: 649
Phone: 16173747580
BLUEPRINT MEDICINES CORP / BPMC FAQ
Can you describe the business of BLUEPRINT MEDICINES CORP?
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
What is the current price of BPMC stock?
The current stock price of BPMC is 129.46 USD. The price increased by 0.14% in the last trading session.
Does BPMC stock pay dividends?
BPMC does not pay a dividend.
What is the ChartMill technical and fundamental rating of BPMC stock?
BPMC has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of BLUEPRINT MEDICINES CORP (BPMC) based on its PE ratio?
BLUEPRINT MEDICINES CORP (BPMC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.22).
Can you provide the market cap for BLUEPRINT MEDICINES CORP?
BLUEPRINT MEDICINES CORP (BPMC) has a market capitalization of 8.37B USD. This makes BPMC a Mid Cap stock.